August 1, 2024Open Access

Vonoprazan as a Long-term Maintenance Treatment for Erosive Esophagitis: VISION, a 5-Year, Randomized, Open-label Study

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Acid secretion inhibitors are associated with hypergastrinemia, which can lead to gastric mucosal changes. Potassium-competitive acid blockers, such as vonoprazan, are more potent than proton pump inhibitors, but long-term safety data are lacking.

Leer artículo completoexternamente

Me gusta

Guardar

Ver artículo completo

Cite This Study

Uemura et al. (Thu,) studied this question.

synapsesocial.com/papers/68e5dc44b6db6435875717ea https://doi.org/https://doi.org/10.1016/j.cgh.2024.08.004

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Multiple gastric carcinoids and endocrine cell micronests in type A gastritis: Nuclear morphometric and immunohistochemical analysis2005 · 12 citations
2Gastric polyps: a retrospective cohort analysisof 23,668 endoscopies indicates changingepidemiological and phenotypic characteristics2024 · 4 citations
3Characterization of a Novel Potassium-Competitive Acid Blocker of the Gastric H,K-ATPase, 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438)2011 · 147 citations
4Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial2022 · 143 citations
5Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study2017 · 118 citations

Me gusta

Guardar

Ver artículo completo